Actinic Keratosis Treatment Market Share Report 2023-2032

Actinic Keratosis Treatment Market - By Therapy (Photodynamic Therapy, Surgery, Topical), By Drug Class (NSAIDs, Nucleoside Metabolic Inhibitor), By End-use (Hospitals & Oncology Centers, Dermatology Clinics) & Forecast 2023 - 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology

1.1&nbsp;&nbsp;&nbsp; Market definition

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Forecast parameters

1.4&nbsp;&nbsp;&nbsp; COVID-19 impact analysis at global level

1.5&nbsp;&nbsp;&nbsp; Data validation

1.6&nbsp;&nbsp;&nbsp; Data Sources

1.6.1&nbsp;&nbsp;&nbsp; Primary

1.6.2&nbsp;&nbsp;&nbsp; Secondary

1.6.2.1&nbsp;&nbsp;&nbsp;Paid sources

1.6.2.2&nbsp;&nbsp;&nbsp;Public sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Actinic keratosis treatment industry 3600&nbsp;synopsis, 2018 &ndash; 2032

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Regional trends

2.1.3&nbsp;&nbsp;&nbsp; Therapy trends

2.1.4&nbsp;&nbsp;&nbsp; Drug class trends

2.1.5&nbsp;&nbsp;&nbsp; End-use trends

Chapter 3&nbsp;&nbsp;&nbsp;Actinic Keratosis Treatment Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Rising prevalence of actinic keratosis

3.2.1.2&nbsp;&nbsp;&nbsp;Favourable reimbursement policies

3.2.1.3&nbsp;&nbsp;&nbsp;Growing demand for minimally invasive procedures

3.2.1.4&nbsp;&nbsp;&nbsp;Increasing number of drug approvals and novel therapies

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;Risk and side effects associated with available treatment options

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.3.1&nbsp;&nbsp;&nbsp; By therapy

3.3.2&nbsp;&nbsp;&nbsp; By drug class

3.3.3&nbsp;&nbsp;&nbsp; By end-use

3.4&nbsp;&nbsp;&nbsp; COVID- 19 impact analysis

3.5&nbsp;&nbsp;&nbsp; Technological advancements

3.6&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6.1&nbsp;&nbsp;&nbsp; U.S.

3.6.2&nbsp;&nbsp;&nbsp; Europe

3.7&nbsp;&nbsp;&nbsp; Pipeline analysis

3.8&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.9&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis, 2022

4.3&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategy dashboard

4.6&nbsp;&nbsp;&nbsp; Strategic outlook matrix

Chapter 5&nbsp;&nbsp;&nbsp;Actinic Keratosis Treatment Market Size and Forecast, By Therapy (USD Million)

5.1&nbsp;&nbsp;&nbsp; Key trends, by therapy

5.2&nbsp;&nbsp;&nbsp; Photodynamic Therapy

5.3&nbsp;&nbsp;&nbsp; Surgery

5.4&nbsp;&nbsp;&nbsp; Topical Medications

Chapter 6&nbsp;&nbsp;&nbsp;Actinic Keratosis Treatment Market Size and Forecast, By Drug Class (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends, by drug class

6.2&nbsp;&nbsp;&nbsp; NSAIDs

6.3&nbsp;&nbsp;&nbsp; Nucleoside Metabolic Inhibitor

6.4&nbsp;&nbsp;&nbsp; Immune Response Modifiers

6.5&nbsp;&nbsp;&nbsp; Photoenhancers

Chapter 7&nbsp;&nbsp;&nbsp;Actinic Keratosis Treatment Market Size and Forecast, By End-use (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends, by end-use

7.2&nbsp;&nbsp;&nbsp; Hospitals and Oncology Centers

7.3&nbsp;&nbsp;&nbsp; Dermatology Clinics

7.4&nbsp;&nbsp;&nbsp; Homecare

7.5&nbsp;&nbsp;&nbsp; Others

Chapter 8&nbsp;&nbsp;&nbsp;Actinic Keratosis Treatment Market Size and Forecast, By Region (USD Million)

8.1&nbsp;&nbsp;&nbsp; Key trends, by region

8.2&nbsp;&nbsp;&nbsp; North America

8.2.1&nbsp;&nbsp;&nbsp; U.S.

8.2.2&nbsp;&nbsp;&nbsp; Canada

8.3&nbsp;&nbsp;&nbsp; Europe

8.3.1&nbsp;&nbsp;&nbsp; Germany

8.3.2&nbsp;&nbsp;&nbsp; UK

8.3.3&nbsp;&nbsp;&nbsp; France

8.3.4&nbsp;&nbsp;&nbsp; Spain

8.3.5&nbsp;&nbsp;&nbsp; Italy

8.3.6&nbsp;&nbsp;&nbsp; Poland

8.3.7&nbsp;&nbsp;&nbsp; Sweden

8.3.8&nbsp;&nbsp;&nbsp; The Netherlands

8.3.9&nbsp;&nbsp;&nbsp; Rest of Europe

8.4&nbsp;&nbsp;&nbsp; Asia Pacific

8.4.1&nbsp;&nbsp;&nbsp; Japan

8.4.2&nbsp;&nbsp;&nbsp; China

8.4.3&nbsp;&nbsp;&nbsp; India

8.4.4&nbsp;&nbsp;&nbsp; Australia

8.4.5&nbsp;&nbsp;&nbsp; South Korea

8.4.6&nbsp;&nbsp;&nbsp; Indonesia

8.4.7&nbsp;&nbsp;&nbsp; Philippines

8.4.8&nbsp;&nbsp;&nbsp; Malaysia

8.4.9&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

8.5&nbsp;&nbsp;&nbsp; Latin America

8.5.1&nbsp;&nbsp;&nbsp; Brazil

8.5.2&nbsp;&nbsp;&nbsp; Mexico

8.5.3&nbsp;&nbsp;&nbsp; Argentina

8.5.4&nbsp;&nbsp;&nbsp; Columbia

8.5.5&nbsp;&nbsp;&nbsp; Chile

8.5.6&nbsp;&nbsp;&nbsp; Peru

8.5.7&nbsp;&nbsp;&nbsp; Rest of Latin America

8.6&nbsp;&nbsp;&nbsp; MEA

8.6.1&nbsp;&nbsp;&nbsp; South Africa

8.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

8.6.3&nbsp;&nbsp;&nbsp; UAE

8.6.4&nbsp;&nbsp;&nbsp; Israel

8.6.5&nbsp;&nbsp;&nbsp; Turkey

8.6.6&nbsp;&nbsp;&nbsp; Iran

8.6.7&nbsp;&nbsp;&nbsp; Rest of MEA

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

9.1&nbsp;&nbsp;&nbsp; Sun Pharmaceutical Industries Ltd

9.2&nbsp;&nbsp;&nbsp; Galderma S.A.

9.3&nbsp;&nbsp;&nbsp; Almirall, S.A.

9.4&nbsp;&nbsp;&nbsp; LEO Pharma A/S

9.5&nbsp;&nbsp;&nbsp; Biofrontera AG

9.6&nbsp;&nbsp;&nbsp; Ortho Dermatologics (Bausch Health Companies Inc.)

9.7&nbsp;&nbsp;&nbsp; Hill Dermaceuticals, Inc.

9.8&nbsp;&nbsp;&nbsp; Cipher Pharmaceuticals Inc.

9.9&nbsp;&nbsp;&nbsp; Spear Pharmaceuticals

9.10&nbsp;&nbsp;&nbsp; Tolmar Inc

9.11&nbsp;&nbsp;&nbsp; Vidac Pharma Holding PLC

9.12&nbsp;&nbsp;&nbsp; Athenex, Inc. 
&nbsp;

Actinic Keratosis Treatment Market

Get a free sample of this report